Jump to content
GET YOUR FLU VACCINE!

Search the Community

Showing results for tags 'breast cancer'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • The LuPUS Message Board
    • Announcements
    • What is the LuPUS Message Board?
    • A Welcome to New Members
    • User Problems
    • Links
  • Medical
    • Medical News 2003
    • Medical News 2004
    • Medical News 2005
    • Medical News 2006
    • Medical News 2007
    • Medical News 2008
    • Medical News 2009
    • Medical News 2010
    • Medical News 2011
    • Medical News 2012
    • Medical News 2013
    • Medical News 2014
    • Medical News 2015
    • Medical News 2016
    • Medical News 2017
    • Medical News 2018
    • Medical News 2019
    • Medical News 2020
    • Medical News 2021
    • Coronavirus: COVID-19
    • Medication & Therapy
    • Lupus and Pregnancy
    • Sjögren’s syndrome
    • Lymphoedema
    • Marginal Zone Lymphoma
  • Non-Medical
    • LuPUS Message Board
  • Public
    • Guest & Test Messages
    • Free Offers
    • Contributors

Blogs

  • Admin
  • Admin
  • Changes To My Diet For Health Reasons

Categories

There are no results to display.

There are no results to display.


Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


AIM


MSN


Website URL


ICQ


Yahoo


Jabber


Skype


Surname (Last or Family name)


First name


Date of Birth


Country


Location


Interests

Found 2 results

  1. BMJ 2011; 343:d6905 doi: 10.1136/bmj.d6905 (Published 26 October 2011) Cite this as: BMJ 2011; 343:d6905 News Breast cancer screening is to be reviewed, cancer tsar announces Nigel Hawkes +Author Affiliations The leaflet sent to women in England who are called for breast cancer screening is to be rewritten for the second time, and the effectiveness of screening is to be reviewed by an independent panel, as the Department of Health moves to resolve growing doubts over the programme. The undertakings are announced today in the BMJ by the national cancer director, Mike Richards (BMJ 2011;343:d6843, doi:10.1136/bmj.d6894). Although he backs the advice of the Advisory Committee on Breast Cancer Screening that the programme saves lives and does more good than harm, he says that he will have no hesitation in putting a contrary view before ministers if the review should reach a different conclusion. He has also promised a new approach to writing the leaflets for each screening programme, with the breast screening leaflet—described by critics in a letter to the Times as “patronising, coercive in tone, and parsimonious with the facts”—as one of the first. An independent team is being commissioned to lead the work and will take account of current thinking on how benefits and harms can best be presented so as to promote informed choice. The current leaflet was last revised as recently as December 2010 after criticism in the BMJ (2009;338:b86, doi:10.1136/bmj.b86) and in the letter to the Times on 19 February 2009 by 23 signatories, led by Michael Baum, professor emeritus of surgery at University College London, and including Susan Bewley, professor of complex obstetrics at King’s College London. Professor Richards’s new undertakings are published in response to an open letter from Professor Bewley, also published today by the BMJ (2011;343:d6894, doi:10.1136/bmj.d6843). In it she says that she is not convinced that Professor Richards has challenged his experts “competently and mercilessly, rather than hidden behind them.” The row over breast cancer screening relies principally on studies by Peter Gøtzsche and colleagues from the Nordic Cochrane Centre. They say that the leaflet exaggerates the benefits and fails to give due weight to the harms, including that of being treated unnecessarily. Although the latest leaflet says that one death from breast cancer is prevented for every 400 women screened for 10 years, the Nordic team says that the number needed to screen is 2000. At the same time, 10 healthy women will become cancer patients and will be treated unnecessarily and about 200 healthy women will experience a false alarm. The leaflet does refer to the risk of needless treatment but does not attempt to quantify it. It records that a quarter of women found to have breast cancer will have the early form, ductal carcinoma in situ, and adds, “We don’t know which cases of DCIS become harmful so we offer these women treatment.” Dr Gøetzsche also contests the claim made in the leaflet that 1400 lives are saved every year in England by screening. In her open letter Professor Bewley says that this number has not been subjected to proper scrutiny and that when she raised the issue privately with Professor Richards he said that a large majority of UK experts disagreed with the methods used by the Cochrane group. “Inadequate and unpersuasive,” says Professor Bewley of Professor Richards’s response. Professor Richards has gone some way towards meeting the critics’ demands by saying that an independent group will rewrite the leaflets, rather than those involved in the programme, who are charged by critics with having a conflict of interest. The review of the evidence will be led by Professor Richards and Harpal Kumar, chief executive of Cancer Research UK. Independent advisers who have never published on breast screening are being sought. Notes Cite this as: BMJ 2011;343:d6905
  2. BMJ 2011; 343:d6905 doi: 10.1136/bmj.d6905 (Published 26 October 2011) Cite this as: BMJ 2011; 343:d6905 News Breast cancer screening is to be reviewed, cancer tsar announces Nigel Hawkes +Author Affiliations The leaflet sent to women in England who are called for breast cancer screening is to be rewritten for the second time, and the effectiveness of screening is to be reviewed by an independent panel, as the Department of Health moves to resolve growing doubts over the programme. The undertakings are announced today in the BMJ by the national cancer director, Mike Richards (BMJ 2011;343:d6843, doi:10.1136/bmj.d6894). Although he backs the advice of the Advisory Committee on Breast Cancer Screening that the programme saves lives and does more good than harm, he says that he will have no hesitation in putting a contrary view before ministers if the review should reach a different conclusion. He has also promised a new approach to writing the leaflets for each screening programme, with the breast screening leaflet—described by critics in a letter to the Times as “patronising, coercive in tone, and parsimonious with the facts”—as one of the first. An independent team is being commissioned to lead the work and will take account of current thinking on how benefits and harms can best be presented so as to promote informed choice. The current leaflet was last revised as recently as December 2010 after criticism in the BMJ (2009;338:b86, doi:10.1136/bmj.b86) and in the letter to the Times on 19 February 2009 by 23 signatories, led by Michael Baum, professor emeritus of surgery at University College London, and including Susan Bewley, professor of complex obstetrics at King’s College London. Professor Richards’s new undertakings are published in response to an open letter from Professor Bewley, also published today by the BMJ (2011;343:d6894, doi:10.1136/bmj.d6843). In it she says that she is not convinced that Professor Richards has challenged his experts “competently and mercilessly, rather than hidden behind them.” The row over breast cancer screening relies principally on studies by Peter Gøtzsche and colleagues from the Nordic Cochrane Centre. They say that the leaflet exaggerates the benefits and fails to give due weight to the harms, including that of being treated unnecessarily. Although the latest leaflet says that one death from breast cancer is prevented for every 400 women screened for 10 years, the Nordic team says that the number needed to screen is 2000. At the same time, 10 healthy women will become cancer patients and will be treated unnecessarily and about 200 healthy women will experience a false alarm. The leaflet does refer to the risk of needless treatment but does not attempt to quantify it. It records that a quarter of women found to have breast cancer will have the early form, ductal carcinoma in situ, and adds, “We don’t know which cases of DCIS become harmful so we offer these women treatment.” Dr Gøetzsche also contests the claim made in the leaflet that 1400 lives are saved every year in England by screening. In her open letter Professor Bewley says that this number has not been subjected to proper scrutiny and that when she raised the issue privately with Professor Richards he said that a large majority of UK experts disagreed with the methods used by the Cochrane group. “Inadequate and unpersuasive,” says Professor Bewley of Professor Richards’s response. Professor Richards has gone some way towards meeting the critics’ demands by saying that an independent group will rewrite the leaflets, rather than those involved in the programme, who are charged by critics with having a conflict of interest. The review of the evidence will be led by Professor Richards and Harpal Kumar, chief executive of Cancer Research UK. Independent advisers who have never published on breast screening are being sought. Notes Cite this as: BMJ 2011;343:d6905
×
×
  • Create New...

Important Information